{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:22Z","timestamp":1793730982402,"version":"4.6.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["452022317"],"award-info":[{"award-number":["452022317"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK111995"],"award-info":[{"award-number":["K23 DK111995"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03 DK132440-01"],"award-info":[{"award-number":["R03 DK132440-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1053\/j.gastro.2024.05.036","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T13:48:30Z","timestamp":1719582510000},"page":"29-52.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease"],"prefix":"10.1053","volume":"168","author":[{"given":"Arno R.","family":"Bourgonje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Mehandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.05.036_bib1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.05.036_bib2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.05.036_bib3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrgastro.2017.110","article-title":"The IBD interactome: an integrated view of aetiology, pathogenesis and therapy","volume":"14","author":"de Souza","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.05.036_bib6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2024.05.036_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barr\u00e9","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.05.036_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.mucimm.2023.08.001","article-title":"Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease","volume":"16","author":"Mehandru","year":"2023","journal-title":"Mucosal Immunol"},{"key":"10.1053\/j.gastro.2024.05.036_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib10","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","article-title":"Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease","volume":"34","author":"Almradi","year":"2020","journal-title":"BioDrugs"},{"key":"10.1053\/j.gastro.2024.05.036_bib12","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ecco-jcc\/jjab188","article-title":"Evolution of IL-23 blockade in inflammatory bowel disease","volume":"16","author":"Danese","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40265-023-01882-9","article-title":"Targeting IL-23 for IBD: rationale and progress to date","volume":"83","author":"Vuyyuru","year":"2023","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2024.05.036_bib14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib18","article-title":"Risankizumab versus ustekinumab for patients with moderate to severe Crohn\u2019s disease: results from the phase 3b SEQUENCE study","volume":"11","author":"Peyrin-Biroulet","year":"2023","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2024.05.036_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2024.05.036_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1172\/JCI200317464","article-title":"Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells","volume":"112","author":"Becker","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2024.05.036_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.05.036_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1189\/jlb.0810456","article-title":"The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity","volume":"89","author":"Liu","year":"2011","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1053\/j.gastro.2024.05.036_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.aidm.2015.04.002","article-title":"Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity","volume":"3","author":"El-Bassat","year":"2016","journal-title":"Adv Dig Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib24","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1053\/j.gastro.2024.05.036_bib25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.175","article-title":"Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease","volume":"40","author":"Barrett","year":"2008","journal-title":"Nat Genet"},{"key":"10.1053\/j.gastro.2024.05.036_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2024.05.036_bib27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2024.05.036_bib28","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20061082","article-title":"IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis","volume":"203","author":"Kullberg","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib29","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2024.05.036_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2010.08.010","article-title":"Interleukin-23 drives intestinal inflammation through direct activity on T cells","volume":"33","author":"Ahern","year":"2010","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2024.05.036_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2024.05.036_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2024.05.036_bib34","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","article-title":"Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice","volume":"132","author":"Elson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","article-title":"Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease","volume":"3","author":"Atreya","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib36","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.05.036_bib37","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.celrep.2016.07.054","article-title":"Epithelial IL-23R signaling licenses protective IL-22 responses in intestinal inflammation","volume":"16","author":"Aden","year":"2016","journal-title":"Cell Rep"},{"key":"10.1053\/j.gastro.2024.05.036_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/mi.2011.54","article-title":"Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice","volume":"5","author":"Cox","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1053\/j.gastro.2024.05.036_bib39","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1084\/jem.20171029","article-title":"ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS-STING","volume":"21","author":"Aden","year":"2018","journal-title":"J\u00a0Exp Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/mi.2013.33","article-title":"IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism","volume":"7","author":"Eken","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1053\/j.gastro.2024.05.036_bib41","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ecco-jcc\/jjy099","article-title":"Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn's disease: results from a randomised phase II biopsy sub-study","volume":"12","author":"Visvanathan","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib42","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.05.036_bib43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.05.036_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964420","article-title":"A\u00a0non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"MAbs"},{"key":"10.1053\/j.gastro.2024.05.036_bib46","doi-asserted-by":"crossref","unstructured":"Daniele SG, Eldirany SA, Ho M, et\u00a0al. Structural basis for differential p19 targeting by IL-23 biologics. Preprint. Posted online March 9, 2023. bioRxiv 2023.03.09.531913.","DOI":"10.1101\/2023.03.09.531913"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2024.05.036_bib47","article-title":"P165 Guselkumab binding to CD64+ IL-23\u2013producing myeloid cells enhances potency for neutralizing IL-23 signaling","volume":"18","author":"Atreya","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40262-019-00759-z","article-title":"Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials","volume":"58","author":"Suleiman","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.gastro.2024.05.036_bib52","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1111\/bcp.15364","article-title":"Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis","volume":"88","author":"Tran","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2024.05.036_bib53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/cts.13197","article-title":"Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis","volume":"15","author":"Chen","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1053\/j.gastro.2024.05.036_bib54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1208\/s12248-019-0352-8","article-title":"Determination of IL-23 pharmacokinetics by highly sensitive accelerator mass spectrometry and subsequent modeling to project IL-23 suppression in psoriasis patients treated with anti-IL-23 antibodies","volume":"21","author":"Zhang","year":"2019","journal-title":"AAPS J"},{"key":"10.1053\/j.gastro.2024.05.036_bib55","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.05.036_bib56","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib57","doi-asserted-by":"crossref","first-page":"i026","DOI":"10.1093\/ecco-jcc\/jjab232.023","article-title":"OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn\u2019s Disease: week 48 analyses from the phase 2 GALAXI 1 study","volume":"16","author":"Danese","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib58","doi-asserted-by":"crossref","unstructured":"Panaccione R, Danese S, Feagan B, et\u00a0al. Abstract 1057b: Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn\u2019s disease: results of the GALAXI 2 & 3 phase 3 studies. Presented at: Digestive Disease Week 2024; May 18\u201321, 2024; Washington, DC.","DOI":"10.1016\/S0016-5085(24)05019-4"},{"key":"10.1053\/j.gastro.2024.05.036_bib59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib60","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0016-5085(21)00835-0","article-title":"132 Efficacy and safety of mirikizumab after 52-weeks maintenance treatment in patients with moderate-to-severe Crohn\u2019s disease","volume":"6","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib62","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.05.036_bib63","doi-asserted-by":"crossref","unstructured":"Allegretti JR, Peyrin-Biroulet L, Feagan BG, et\u00a0al. Abstract 913b: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study. Presented at: Digestive Disease Week 2023; May 7\u20139, 2023; Chicago, IL.","DOI":"10.1016\/S0016-5085(23)04757-1"},{"key":"10.1053\/j.gastro.2024.05.036_bib64","doi-asserted-by":"crossref","unstructured":"Rubin DT, Allegretti JR, Panes J, et\u00a0al. Abstract 759: The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR maintenance study. Presented at: Digestive Disease Week 2024; May 18\u201321, 2024; Washington, DC.","DOI":"10.1016\/S0016-5085(24)00910-7"},{"key":"10.1053\/j.gastro.2024.05.036_bib65","doi-asserted-by":"crossref","first-page":"i028","DOI":"10.1093\/ecco-jcc\/jjab232.025","article-title":"OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study","volume":"16","author":"D\u2019Haens","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib66","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib67","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment: interim results from the LUCENT-3 open-label extension study","volume":"11","author":"Sands","year":"2023","journal-title":"United European Gastroenterol"},{"key":"10.1053\/j.gastro.2024.05.036_bib68","first-page":"OP021","article-title":"Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study","volume":"11","author":"Louis","year":"2023","journal-title":"United European Gastroenterol"},{"key":"10.1053\/j.gastro.2024.05.036_bib70","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1093\/ecco-jcc\/jjx002.128","article-title":"The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD","volume":"11","author":"Cheng","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib71","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.14309\/01.ajg.0000592540.43886.35","article-title":"Safety, tolerability, and pharmacokinetics of PTG-200, an oral GI-restricted peptide antagonist of IL-23 receptor, in normal healthy volunteers","volume":"114","author":"Cheng","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.05.036_bib72","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J\u00a0Med Chem"},{"key":"10.1053\/j.gastro.2024.05.036_bib73","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib74","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1053\/j.gastro.2024.05.036_bib75","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib76","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97236-0","article-title":"Preclinical development of a bispecific TNF\u03b1\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease","volume":"11","author":"Roberts","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2024.05.036_bib78","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib80","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.05.036_bib81","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.05.036_bib82","doi-asserted-by":"crossref","first-page":"i042","DOI":"10.1093\/ecco-jcc\/jjab232.035","volume":"16","author":"Sands","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib83","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib84","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn's disease: a systematic review and network meta-analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib85","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.05.036_bib86","doi-asserted-by":"crossref","first-page":"P328","DOI":"10.1093\/ecco-jcc\/jjab232.455","article-title":"In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in inflammatory bowel disease","volume":"16","author":"Perrigoue","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.05.036_bib87","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.05.036_bib88","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jdv.18042","article-title":"Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review","volume":"36","author":"Norden","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1053\/j.gastro.2024.05.036_bib89","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1038\/ncomms7525","article-title":"IL-23-mediated mononuclear phagocyte crosstalk protects mice from Citrobacter rodentium-induced colon immunopathology","volume":"6","author":"Aychek","year":"2015","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2024.05.036_bib90","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","article-title":"Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis","volume":"35","author":"Bots","year":"2021","journal-title":"BioDrugs"},{"key":"10.1053\/j.gastro.2024.05.036_bib91","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23\u2013specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.gastro.2024.05.036_bib92","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4049\/immunohorizons.2300003","article-title":"Guselkumab more effectively neutralizes psoriasis-associated histologic, transcriptomic, and clinical measures than ustekinumab","volume":"7","author":"Campbell","year":"2023","journal-title":"Immunohorizons"},{"key":"10.1053\/j.gastro.2024.05.036_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524051242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524051242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T13:55:27Z","timestamp":1738590927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524051242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0016508524051242"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.05.036","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}